All events are in Central time unless specified.

Food for Health Seminar Series

12:00 am – 1:00 pm
Zoom-> Room: Password: NFHC
Allie Claypool,
Dr. Paul McMurdie will present at the Nebraska Food for Health Seminar Series. This speaker has been selected by the NFHC Graduate Student Council.

Title: “Novel Probiotic Improves Glucose Control in Subjects with Type 2 Diabetes: Double Blind, Randomized Placebo-Controlled Trial of Safety and Metabolic Effects”

Talk Abstract:
A growing body of evidence suggests that specific, naturally occurring bacteria are underrepresented in the intestinal tracts of subjects with type 2 diabetes (T2D), and that their functions are important to glucose and insulin homeostasis. While dozens of trials have investigated the effect of some form of probiotic for T2D, nearly all suffered from being limited to commonly-available microorganisms not specifically recognized in the disease and trial duration that is too short to detect changes in glycated hemoglobin (A1c), a key measure of glucose control and disease severity. In this presentation I will show the design and results of an early-stage randomized controlled trial that tests whether a novel probiotic formulation composed of disease-selected, strictly anaerobic bacteria could enhance dietary management of T2D. I will also describe some of the prerequisite developments needed to acquire this trial data, especially (1) manufacturing two novel probiotic formulations in our purpose built FDA-registered cGMP facility (2) establishing consistent live-cell dose (3) confirming safety at target doses in both animal and human studies, and (4) conducting a 12-week parallel, double-blind, placebo-controlled study in which subjects previously diagnosed with T2D (n=76) were randomly assigned to a twice-daily regimen of placebo or one of the two novel probiotics. No safety or tolerability issues were observed. Compared to the placebo group, subjects administered WBF-011 (a 5-strain formulation containing inulin, Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Bifidobacterium infantis and Eubacterium hallii) showed improved glucose control that was statistically significant, clinically relevant, and observed in two distinct clinical measures. To our knowledge, this is the first randomized controlled trial to administer 4 of the 5 strains to human subjects with type 2 diabetes. Additional exploratory measurements from subject stool and blood will also be discussed.

Speaker Bio:
Paul McMurdie received a B.S. in Chemical Engineering from Univ of Arizona, and then moved to the SF Bay Area where he received his M.S. and PhD in Environmental Engineering and genomics at Stanford University, followed by a postdoc in Statistics. Among other topics, Paul has co-authored articles on human microbiome investigations of preterm birth, inflammatory bowel disease, colorectal cancer, and type-2 diabetes. Paul is perhaps better known for co-authoring articles on microbiome analysis methods and their implementations, including three articles on normalization, exploratory analysis, and exact sequence resolution of amplicons that have each garnered more than 1000 citations and ~100,000 views. Correspondingly, Paul created and maintains an open-source R package for microbiome exploratory analysis, phyloseq, and is a contributing developer to dada2, each of which has been among the top 5% most-downloaded packages in Bioconductor for the past several years. Paul made the jump to industry 6 years ago, and is currently Senior Staff Data Scientist at Pendulum Therapeutics in San Francisco, where he created a collaborative team of data scientists developing and utilizing analysis methods for the discovery and production of novel efficacious (“next gen”) probiotics. These products include the new “Pendulum Glucose Control,” which had a successful early stage human clinical trial for the treatment of type-2 diabetes, and is now available for direct-to-consumer purchase.

Seminar: Noon-1PM

Remote seminar via Zoom->
Password: NFHC

Please reach out to Hugh McCullough (email: to schedule remote meeting time on Friday, May 1st with this speaker.

Download this event to my calendar